Interview: CellCentric Prostate Cancer Drug Promises Much

The Cambridge-based company's CEO Will West tells Scrip that CCS1477 has shown a lot of potential for patients with late-stage prostate cancer who are resistant to second-line anti-androgen drugs like Zytiga and Xtandi and the $26m it has just raised will help fund development of the epigenetic therapy up to Phase IIb.

Prostate cancer
CellCentric says it has a first-in-class prostate cancer therapy • Source: Shutterstock

Having investigated around 60 potential epigenetic-related drug targets, the UK's CellCentric Ltd. believes it has found one that is a first-in-class candidate for treatment-resistant prostate cancer and is heading to the clinic with $26m in new funds.

The Cambridge-headquartered privately held biotech has raised all the cash from one of its existing backers - Morningside Venture Investments...

More from Anticancer

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

More from Therapy Areas

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.